蛋白酶抑制剂防治器官缺血再灌注损伤研究进展  

Research advances of protease inhibitors on solid organ ischemia-reperfusion injury

作　　者：谢礼波[1] 卢一平[1] 

机构地区：[1]四川大学华西医院泌尿外科,成都610041

出　　处：《中华移植杂志（电子版）》2012年第1期42-46,共5页Chinese Journal of Transplantation(Electronic Edition)

基　　金：国家重点基础研究发展计划(2009CB522401)

摘　　要：缺血再灌注损伤(IRI)是器官移植常见的一种病理生理过程。蛋白酶抑制剂可以通过稳定溶酶体膜、抑制溶酶体酶及促炎性细胞因子释放、清除氧自由基、减轻炎症反应等途径,对多种器官IRI发挥积极的保护作用。蛋白酶抑制剂可分为非选择性和选择性两大类。前者主要有乌司他丁、加贝酯、MG132等,后者包括钙蛋白酶抑制剂、丝氨酸蛋白酶抑制剂、人中性粒细胞弹性蛋白酶抑制剂等。随着对蛋白酶抑制剂在防治IRI中作用和机制研究的不断深入,其对IRI的防治价值将逐渐明晰起来。Ischemia-reperfusion injury （IRI） is a common pathophysiological process in clinical organ transplantation. Protease inhibitors can protect organs from IRI by stabilizing the lysosomal membrane, restraining the release of lysosomal enzyme and proinflammatory cytokines, removing free oxygen radicals, and reducing inflammatory reactions. There are two kinds of protease inhibitors,including nonselective ones such as ulinastatin, gabexate, and MG132 and selective ones such as calpain inhibitors, serine protease inhibitors, and human neutrophil elastase. As we know more about the impact of protease inhibitors on IRI and the underlying mechanisms, their values in IRI prevention and treatment will become more evident.

关 键 词：缺血再灌注损伤 蛋白酶抑制剂 器官移植 

分 类 号：R617[医药卫生—外科学]